Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity.
Description | Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively), has antitumor and antiangiogenic activity. |
Targets&IC50 | Flk-1:6 nM (ki), PDGFRβ:5 nM (ki) |
In vivo | Administration of toceranib significantly decreased the number and percentage of Treg in the peripheral blood of dogs with cancer. Dogs receiving toceranib and CYC demonstrated a significant increase in serum concentrations of IFN-γ, which was inversely correlated with Treg numbers after 6 weeks of combination treatment[1]. |
Synonyms | SU11654, PHA 291639E, 托西尼布 |
Molecular Weight | 396.46 |
Formula | C22H25FN4O2 |
CAS No. | 356068-94-5 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 2.4 mg/mL (6.05 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Toceranib 356068-94-5 蛋白酪氨酸激酶 血管生成 PDGFR VEGFR c-Kit PHA 291639E SCFR SU-11654 CD117 Vascular endothelial growth factor receptor SU 11654 inhibit Platelet-derived growth factor receptor Inhibitor SU11654 inhibitor